Gamida Cell Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
October 2018
42
About the Report
About the Report
Summary
Gamida Cell Ltd (Gamida) is a developer of cellular and immune therapeutics. The company's products comprise nicord, cordin and NK cell product. Its nicord is developed for the treatment of bone marrow transplantation for patients with high risk leukemia and lymphoma. Gamida's cordin is used for the treatment of non-malignant orphan diseases. The company uses its NAM technology platform and copper chelator based technology for its product development for cell therapy. It undertakes clinical studies for the treatment of blood cancers. The company serves patients with cancer and rare genetic diseases. Gamida is headquartered in Jerusalem, Israel.
Gamida Cell Ltd-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
Gamida Cell Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Gamida Cell Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Gamida Cell Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Gamida Cell Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Gamida Cell Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Gamida Cell Ltd, Medical Devices Deals, 2012 to YTD 2018 10
Gamida Cell Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Gamida Cell Ltd, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Gamida Cell Raises USD 10 Million In Series E Financing 12
Private Equity 14
Gamida Cell Raises USD40 Million in Private Financing 14
Equity Offering 16
Gamida to Raise up to USD69 Million in IPO 16
Acquisition 17
Clal Biotech to Acquire 5% Stake in Gamida Cell from Teva Pharma 17
Novartis to Acquire Additional 2.5% Stake in Gamida Cell for USD15 Million 18
Novartis Pharma Acquires 15% Stake in Gamida Cell for USD35 Million 19
Gamida Cell Ltd-Key Competitors 20
Gamida Cell Ltd-Key Employees 21
Gamida Cell Ltd-Locations And Subsidiaries 22
Head Office 22
Recent Developments 23
Corporate Communications 23
Sep 18, 2018: Gamida Cell names Robert Blum as Board Chairman 23
Aug 06, 2018: Gamida Cell expands its leadership team with the appointment of Jaren Madden as vice president, investor relations and corporate communications 24
Jul 23, 2018: Gamida Cell appoints Tzvi Palash as Chief Operating Officer and John Schick as Vice President of Market Access 25
Apr 26, 2018: Gamida Cell Strengthens Leadership Team with Appointments of Josh Hamermesh as Chief Business Officer and Paul Nee as Vice President of Marketing 26
Mar 15, 2018: Gamida Cell Appoints Shai Lankry as Chief Financial Officer 27
Nov 20, 2017: Gamida Cell Appoints Julian Adams, Ph.D., Chairman and Chief Executive Officer 28
Jul 10, 2017: Gamida Cell announces joining of new CMO 29
Jun 05, 2017: Gamida Cell appoints two new board members 30
Product News 31
12/11/2017: Gamida Cell Presents Data from NiCord Development Program at the 2017 ASH Annual Meeting 31
11/01/2017: Gamida Cell to Present New On NiCord at 2017 ASH Annual Meeting 32
07/10/2017: Gamida Cell Names Ronit Simantov, M.D. as Chief Medical Officer 33
06/05/2017: Gamida Cell Appoints Nobel Prize Laureate Professor Roger Kornberg and Immune Oncology Expert Dr. Michael Perry to its Board of Directors 34
04/20/2017: Gamida Cell Announces Publication of Positive Clinical Outcomes from NiCord-Transplanted Patients in the Journal of Biology of Blood and Marrow Transplantation 35
02/20/2018: Gamida Cell to Present Data from NiCord Programs at the 2018 BMT Tandem Meetings 36
Product Approvals 38
Mar 23, 2017: Gamida Cell Receives Additional EMA Orphan Drug Designation for NiCord in Haematopoietic Stem Cell Transplantation 38
Clinical Trials 39
Mar 19, 2018: Gamida Cell to Present Immune Reconstitution Data for its NiCord Program at the 2018 EBMT Annual Meeting 39
Jul 20, 2017: Gamida Cell Obtains USD 3.5 Million Israeli Grant, to Help Support Development of NiCord 40
Feb 28, 2017: Gamida Cell Announces First Patient Transplanted in Phase 3 Registration Study of NiCord for Blood Cancers 41
Appendix 42
Methodology 42
About GlobalData 42
Contact Us 42
Disclaimer 42
List of Figure
List of Figures
Gamida Cell Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Gamida Cell Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Gamida Cell Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Gamida Cell Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Gamida Cell Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Gamida Cell Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Gamida Cell Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Gamida Cell Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Gamida Cell Ltd, Medical Devices Deals, 2012 to YTD 2018 10
List of Table
List of Tables
Gamida Cell Ltd, Pharmaceuticals & Healthcare, Key Facts 2
Gamida Cell Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Gamida Cell Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Gamida Cell Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Gamida Cell Ltd, Deals By Therapy Area, 2012 to YTD 2018 9
Gamida Cell Ltd, Medical Devices Deals, 2012 to YTD 2018 10
Gamida Cell Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Gamida Cell Raises USD 10 Million In Series E Financing 12
Gamida Cell Raises USD40 Million in Private Financing 14
Gamida to Raise up to USD69 Million in IPO 16
Clal Biotech to Acquire 5% Stake in Gamida Cell from Teva Pharma 17
Novartis to Acquire Additional 2.5% Stake in Gamida Cell for USD15 Million 18
Novartis Pharma Acquires 15% Stake in Gamida Cell for USD35 Million 19
Gamida Cell Ltd, Key Competitors 20
Gamida Cell Ltd, Key Employees 21
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.